Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply during Tuesday’s session after the company released topline data from...
Pfizer, Inc. (NYSE: PFE) shares are trading higher on the first trading day of 2024 after the stock lost more than 40% in 2023. Here's a look a...
Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday following positive analyst coverage from Oppenheimer. What Happened: Oppenhe...
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. The forthcoming year will provide the first...
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023. ...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 27.73% on an annualized basis producing an average annual return of 42.1...
The U.S. Food and Drug Administration (FDA) identified several quality control issues at the primary manufacturing facility of Moderna Inc.&nb...
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. In "Sell Nokia Stock, C...
The CNN Money Fear and Greed index showed some easing in overall market sentiment, but the index remained in the "Greed" zone on Thursday...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...